



Patent Application
Attorney Docket No. PC25223A-1

1fw
I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this July, 2005 day of

By _____

(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Stanton McHardy, et al, :

APPLICATION NO.: 10/762,447 : Examiner:

FILING DATE: January 22, 2004 : Group Art Unit: 1714

TITLE: 4-Phenyl-piperidine Compounds and Their Use :
As Modulators of Opioid Receptors

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: July 7, 2005

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

Respectfully submitted,

Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895



JUL 11 2005

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>								ATTY. DOCKET NO. PC25223A			SERIAL NO. 10/762,447							
								APPLICANT Stanton McHardy, et al.										
								FILING DATE January 22, 2004								GROUP 1714		
U.S. PATENT DOCUMENTS																		
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME		CLASS	SUBCLASS	FILED DATE IF APPROPRIATE				
	US	2002	0	0	9	9	2	16	7/25/02	Gibson, et al.		546	208					
FOREIGN PATENT DOCUMENTS																		
DOCUMENT NUMBER									DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION				
	US	2002	0	0	9	9	2	16	7/25/02	Gibson, et al.		546	208	YES	NO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																		
			Le Bourdonnec, B., et al., <i>Bioorganic Medicinal Chemistry Letters</i> , "trans-3,4-Dimethyl-4-(3-carboxamidophenyl) piperidines: A Novel Class of μ -Selective Opioid Antagonists", Vol. 13, pages 4459-4462 (2003)															
EXAMINER				DATE CONSIDERED														
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>																		

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE